BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Prepaid R&D Costs: $48.2M in Q2 2026, down 36.7% from a year earlier.
Latest, Q2 2026
48.2
Period ended Jun 30, 2026
Change on a year earlier
-36.7%
76.2 in Q2 2025
History
35 quarters
Since Q4 2017
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Prepaid Expenses Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). BeOne Medicines Prepaid R&D Costs ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prepaid-rd
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.